News

EB-101, a gene therapy developed by Abeona Therapeutics, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). This designation is granted to investigative therapies that the FDA believes may show a substantial improvement over existing…

Short-term application of the antibiotic gentamicin, either topical or intradermal, reversed the effect of nonsense mutations in a small group of patients with recessive dystrophic epidermolysis bullosa (RDEB) and led to the production of functional type VII collagen protein and anchoring fibrils. RDEB is a severe form of epidermolysis bullosa,…

In a recent update on its drug development program, Fibrocell Science addressed the therapy, FCX-007, it is developing for people with recessive dystrophic epidermolysis bullosa (RDEB). Results from the Phase 1 part of a clinical trial testing FCX-007 will be available soon, according to the company. FCX-007 is a cell…

Amicus Therapeutics, a company developing therapeutics for rare diseases, recently released an update of the company’s clinical trial testing SD-101 as a potential therapy for patients with epidermolysis bullosa. The company’s investigational drug SD-101 is a skin cream designed for the treatment of skin blistering and lesions, and it…

Many adults and children with epidermolysis bullosa simplex (EBS-l) experience pain that can significantly impact their quality of life, but they lack access to adequate pain-management options, a questionnaire-based study found. The study, “Pain and quality of life evaluation in patients with localized epidermolysis bullosa simplex,” was published in…

Cannabinoid therapy developer InMed and French tissue engineering company ATERA have teamed up to develop 3-D human skin models with tissue taken from epidermolysis bullosa (EB) patients. The models will be used to test InMed’s candidate therapy INM-750 in the lab before moving to clinical trials in…

The U.S. Food and Drug Administration (FDA) recently recommended Abeona Therapeutics accelerate the clinical development program of its gene therapy candidate EB-101 for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB), also known as “butterfly skin” syndrome. With the recommendation, which came in a recent Type-C meeting with the…

The European Medicines Agency (EMA) recently granted Tarix Orphan’s lead investigational product TXA127 orphan drug status for the treatment of epidermolysis bullosa (EB). Orphan drug status is granted by regulatory agencies to drugs in development for the treatment of rare diseases, and where the pharmaceutical company will profit…

The first patient has enrolled in a clinical trial evaluating both the efficacy and safety of diacerein 1% ointment (CCP-020) in treating epidermolysis bullosa simplex (EBS), Castle Creek Pharmaceuticals recently announced. The company’s Phase 2/3 DELIVERS clinical trial (NCT03154333) is currently recruiting participants. CCP-020 is a small molecule, engineered to…

The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101,  Abeona Therapeutics’ treatment for the inherited skin disease epidermolysis bullosa, or EB. Importantly, the designation also covers a severe form of the blistering and open-wound disorder known as recessive dystrophic epidermolysis bullosa, or RDEB. The FDA…